Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Urogen Pharma Ltd (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
UroGen Pharma to Present at March 2019 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March:

URGN : 35.47 (-3.67%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results

--Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020

URGN : 35.47 (-3.67%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the market. The...

URGN : 35.47 (-3.67%)
Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Toyota Motor Corporation...

CZZ : 12.06 (-7.44%)
HHC : 107.79 (-2.92%)
URGN : 35.47 (-3.67%)
TM : 120.22 (-0.18%)
MSEX : 56.52 (-3.55%)
MAC : 43.78 (-0.07%)
UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 35.47 (-3.67%)
JPM : 99.76 (-3.02%)
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 35.47 (-3.67%)
JPM : 99.76 (-3.02%)
UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

--All Evaluated Patients in CR Remain Disease Free at Six Months

URGN : 35.47 (-3.67%)
UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 35.47 (-3.67%)
UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

--Submission Supported by Pivotal Phase 3 OLYMPUS Study; Topline Results to be Presented in January 2019

URGN : 35.47 (-3.67%)
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA)...

URGN : 35.47 (-3.67%)
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 35.47 (-3.67%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM),...

URGN : 35.47 (-3.67%)
ACIA : 54.80 (-5.66%)
TCPC : 14.12 (-0.91%)
DORM : 83.31 (-1.78%)
ACGL : 32.06 (-0.71%)
CONE : 52.14 (-0.63%)
Today's Research Reports on Stocks to Watch: UroGen Pharma and Novartis

NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Shares of Novartis and UroGen both saw gains in Tuesday trading. UroGen saw its shares climb after announcing new data presentation from an interim analysis...

URGN : 35.47 (-3.67%)
NVS : 93.42 (-0.26%)
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data...

URGN : 35.47 (-3.67%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar